Latest Expert Opinions

Signal
Opinion
Expert
Chart
TOP PICK
TOP PICK
February 18, 2021
Stockchase Research Editor: Michael O'Reilly Recently reported earnings showed sales rebounding, revenue growth and a positive outlook from management -- meeting, but not beating analyst expectations. Management expects sales growth exceeding 30% next quarter, compared to the pandemic impact a year ago. Cash flow is estimated to have increased by over $230 million over the year and with virtually no debt the company is well positioned. It pays a decent dividend, backed by a 21% payout ratio. We would buy this with a stop-loss at $29, looking to achieve $47.50 -- upside of 25%. Yield 1.59% (Analysts’ price target is $47.50)
Show full opinionHide full opinion
La-Z-Boy Inc. (LZB-N)
February 18, 2021
Stockchase Research Editor: Michael O'Reilly Recently reported earnings showed sales rebounding, revenue growth and a positive outlook from management -- meeting, but not beating analyst expectations. Management expects sales growth exceeding 30% next quarter, compared to the pandemic impact a year ago. Cash flow is estimated to have increased by over $230 million over the year and with virtually no debt the company is well positioned. It pays a decent dividend, backed by a 21% payout ratio. We would buy this with a stop-loss at $29, looking to achieve $47.50 -- upside of 25%. Yield 1.59% (Analysts’ price target is $47.50)
TOP PICK
TOP PICK
February 18, 2021
Stockchase Research Editor: Michael O'Reilly SAH operates car dealerships. Its EchoPark used car business has benefitted from the pandemic, where sales were up 25% over the year and prices rose. They have plans to expand this segment further. New car dealerships held steady as lower volumes were offset by higher prices as well. Margins overall hit a record high at 68%, allowing EPS to beat expectations, up 52% on the year. It pays a small dividend backed by an expected payout ratio of 15% of cash flow. We would buy this with a stop-loss at $30, looking to achieve $51.50 -- 35% potential upside. Yield 0.97% (Analysts’ price target is $51.14)
Show full opinionHide full opinion
Sonic Automotive (SAH-N)
February 18, 2021
Stockchase Research Editor: Michael O'Reilly SAH operates car dealerships. Its EchoPark used car business has benefitted from the pandemic, where sales were up 25% over the year and prices rose. They have plans to expand this segment further. New car dealerships held steady as lower volumes were offset by higher prices as well. Margins overall hit a record high at 68%, allowing EPS to beat expectations, up 52% on the year. It pays a small dividend backed by an expected payout ratio of 15% of cash flow. We would buy this with a stop-loss at $30, looking to achieve $51.50 -- 35% potential upside. Yield 0.97% (Analysts’ price target is $51.14)
TOP PICK
TOP PICK
February 18, 2021
Stockchase Research Editor: Michael O'Reilly D.UN has survived the ravages of the pandemic, it pays an excellent dividend, backed by a 23% payout ratio of cashflow. Trading at 4.5x times earnings and 66% of book, it is good value here. As vaccinations increase and workplaces begin to reopen, this will continue to thrive. We would buy this with a stop-loss at $16, looking to achieve $25 -- upside potential of 28%. Yield 5.18% (Analysts’ price target is $24.96)
Show full opinionHide full opinion
Dream Office REIT (D.UN-T)
February 18, 2021
Stockchase Research Editor: Michael O'Reilly D.UN has survived the ravages of the pandemic, it pays an excellent dividend, backed by a 23% payout ratio of cashflow. Trading at 4.5x times earnings and 66% of book, it is good value here. As vaccinations increase and workplaces begin to reopen, this will continue to thrive. We would buy this with a stop-loss at $16, looking to achieve $25 -- upside potential of 28%. Yield 5.18% (Analysts’ price target is $24.96)
PAST TOP PICK
PAST TOP PICK
February 18, 2021
(A Top Pick Oct 29/20, Up 23.2%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with WMK has achieved its $56 target. To be disciplined we recommend covering 50% of the position and trailing up the stop (from $38) to the original recommended price at $46.
Show full opinionHide full opinion
Weis Markets, Inc. (WMK-N)
February 18, 2021
(A Top Pick Oct 29/20, Up 23.2%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with WMK has achieved its $56 target. To be disciplined we recommend covering 50% of the position and trailing up the stop (from $38) to the original recommended price at $46.
PAST TOP PICK
PAST TOP PICK
February 18, 2021
(A Top Pick Nov 17/20, Up 27.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with CRMT has achieved its $134 target. To be disciplined, we recommending covering 50% of the position and trailing up the stop (from $85) to $120. This would all but guarantee an minimum investment return of 21%.
Show full opinionHide full opinion
(A Top Pick Nov 17/20, Up 27.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with CRMT has achieved its $134 target. To be disciplined, we recommending covering 50% of the position and trailing up the stop (from $85) to $120. This would all but guarantee an minimum investment return of 21%.
Stockchase Research
Price
$132.270
Owned
_N/A
PAST TOP PICK
PAST TOP PICK
February 18, 2021
(A Top Pick Oct 08/20, Up 17.8%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABT has achieved its $128 objective. To be disciplined, we recommend covering 50% of the position and trailing up the stop (from $97) to the original recommended price level at $109.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
February 18, 2021
(A Top Pick Oct 08/20, Up 17.8%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABT has achieved its $128 objective. To be disciplined, we recommend covering 50% of the position and trailing up the stop (from $97) to the original recommended price level at $109.
Stockchase Research
Price
$125.950
Owned
Unknown
HOLD
HOLD
February 18, 2021
A real health conglomerate. Vertically integrated. Inexpensive valuation, at less than 10x. Recent earnings moved the needle down. Market may have been disappointed on 2021 guidance. 12.5% free cashflow yield. An excellent opportunity. The vaccine rollout will be a major contributor to its financial success.
Show full opinionHide full opinion
CVS Health Corp (CVS-N)
February 18, 2021
A real health conglomerate. Vertically integrated. Inexpensive valuation, at less than 10x. Recent earnings moved the needle down. Market may have been disappointed on 2021 guidance. 12.5% free cashflow yield. An excellent opportunity. The vaccine rollout will be a major contributor to its financial success.
Gordon Reid
Price
$71.620
Owned
Yes